Geoffrey Maltzahn - Kaleido Biosciences President Co-Founder

KLDO -  USA Stock  

USD 5.78  0.11  1.94%

  President
Mr. Geoffrey von Maltzahn is the President, CoFounder of the Company. He is a leading innovator and entrepreneur in the microbiome and biotechnology and is a cofounder of companies that have achieved over 3 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has cofounded multiple biotech companies including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals . He recently served as the President of Indigo, where he led the creation of the worlds largest plant microbiome database and development of the companys first commercial products. Von Maltzahn is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiomebased technologies and was recognized with numerous awards, including the prestigious LemelsonMIT student prize, given to the most innovative student at MIT. Von Maltzahns innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his PhD from MIT in the HarvardMIT Division of Health Sciences and Technology.
    Ph.D    
617 674 9000  http://kaleido.com

Kaleido Biosciences Management Efficiency

Kaleido Biosciences has return on total asset (ROA) of (59.77) % which means that it has lost $59.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (161.51) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.23. The value of Return on Average Equity is estimated to slide to -2.37. Kaleido Biosciences Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 68.54 Million. Current Assets is expected to rise to about 58.5 M this year, although the value of Assets Non Current will most likely fall to about 10.1 M.
The company currently holds 21.19 M in liabilities with Debt to Equity (D/E) ratio of 0.3, which may suggest the company is not taking enough advantage from borrowing. Kaleido Biosciences has a current ratio of 7.23, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

PRESIDENT Since

Michael OstrachDynavax Technologies
2016
David JohnsonDynavax Technologies
2014
Ryan SpencerDynavax Technologies
2019
Robert JanssenDynavax Technologies
2018
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. Kaleido Biosciences (KLDO) is traded on NASDAQ Exchange in USA. It is located in 65 Hayden Avenue and employs 82 people. Kaleido Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Kaleido Biosciences Leadership Team

Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geoffrey Maltzahn, President Co-Founder
Jeremy Buzzard, Senior Vice President - Corporate Development
Johannes Vlieg, Chief Scientific Officer
Jerald Korn, General Counsel, Corporate Secretary
Grady Burnett, Director
Mike Bonney, Chairman of the Board, CEO
Bonnie Bassler, Director
John Sculley, Director
Ruth ThieroffEkerdt, Chief Medical Officer
Jeffery Moore, Senior Vice President - Finance & Administration
Theo MelasKyriazi, Independent Director
Clare Fisher, Chief Business Officer

Kaleido Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Kaleido Biosciences Investors Sentiment

The influence of Kaleido Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kaleido. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KLDO

Kaleido Biosciences Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Kaleido Biosciences. What is your trading attitude regarding investing in Kaleido Biosciences? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.